| Execution period | 60 months |
|---|
NSE filing, NSE: NIDAN. Summary written from the filing by ALFA Finder's alert engine.
Nidan Laboratories And Healthcare Ltd: key numbers
- Share price
- ₹13.00
- Market cap
- ₹18.07 Cr
- Revenue (annual)
- ₹25.54 Cr
- Net profit (annual)
- ₹1.51 Cr
- P/E (TTM)
- 12.0×Sector 52.0×
- Promoter holding
- 57.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nidan Laboratories And Healthcare Ltd
All →Nidan Laboratories And Healthcare Other Announcement
Nidan Laboratories and Healthcare Limited submitted a non-applicability intimation for Corporate Governance reports. The company is exempt under SEBI Regulation 15 due to its SME listing.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited conducted its 26th Annual General Meeting on September 28, 2026. Shareholders considered agenda items including financial statement adoption and director re-appointments.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will hold its 26th Annual General Meeting on September 28, 2026. The company has submitted its Annual Report for FY 2025-26.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will convene its 26th Annual General Meeting on September 28, 2026. The board also approved book closure and e-voting schedules.
Nidan Laboratories And Healthcare Board Meeting Date
Nidan Laboratories and Healthcare Limited has scheduled a board meeting for August 20, 2026. The meeting agenda covers general business matters.
Nidan Laboratories And Healthcare Board Meeting Outcome
Nidan Laboratories approved FY26 audited financial results and re-appointed independent directors and statutory auditors. These board decisions ensure operational continuity and regulatory compliance.
Other management change announcements
All →Transgene Biotek Management Change
Transgene Biotek's statutory auditors Eswara Rao & Co. resigned effective 28 October 2026 citing pre-occupation. The company will appoint new auditors per applicable regulations.
Mobavenue AI Tech Management Change
Mobavenue AI Tech appointed Vikram Sheth as Chief of Corporate Development and Investor Relations. He will lead fundraising, acquisitions and investor relations.
Hexaware Technologies Management Change
Hexaware appointed Arjun Shah and Gregory Zeluck as Non-Executive Directors from 28 October 2026. Directors Neeraj Bharadwaj and Julius Genachowski resigned, and Girish Pai's resignation is effective 13 November 2026.
GMR Airports Management Change
GMR Airports appointed Sanjeev Gupta as Executive Director (Deputy CEO) effective 29 October 2026. Non-Executive Director Alexis Riols resigned effective 28 October 2026.
Raymond Realty Management Change
Raymond Realty said joint statutory auditor Chaturvedi & Shah LLP resigned on 28 October 2026 after a dispute over audit fee revision. Walker Chandiok & Co LLP continues as the other statutory auditor.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.